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Abstract
Background: Rubinstein-Taybi syndrome (RTS) is a rare autosomal dominant disorder (prevalence 1:125,000)
characterised by broad thumbs and halluces, facial dysmorphism, psychomotor development delay, skeletal defects,
abnormalities in the posterior fossa and short stature. The known genetic causes are point mutations or deletions
of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene
E1A-binding protein (EP300) (5%).
Case presentation: We describe, for the first time in literature, a RTS Caucasian girl, 14-year-old, with growth
hormone (GH) deficiency, pituitary hypoplasia, Arnold Chiari malformation type 1, double syringomyelic cavity and
a novel CREBBP mutation (c.3546insCC).
Conclusion: We hypothesize that CREBBP mutation we have identified in this patient could be responsible also
for RTS atypical features as GH deficiency and pituitary hypoplasia.
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Background
Clinical overview
Rubinstein-Taybi syndrome (RTS) is an autosomal dom-
inant disease that occurs in 1 out of 125,000 births. The
first description of the syndrome by Rubinstein and Taybi
was in 1963 [1].
RTS is characterized by broad and sometimes laterally
deviated thumbs and halluces, downslanting palpebral
fissures, apparent hypertelorism, long eyelashes, high-
arched eyebrows, prominent nose with columella below
the alae nasi, malpositioned ears with dysplastic helices,
high-arched palate, hypoplastic maxilla. The facial ex-
pression is characteristic: showing grimacing or at least
unusual smile. The finding of talon cusps at the
permanent incisors can be helpful, as these are only
rarely found in other entities [2].
Other physical findings may include a variety of con-
genital heart defects, joint hypermobility and skin
anomalies (hirsutism, naevus flammeus on the forehead,
and keloid formation) [3]. Mental retardation is usual
with an average IQ between 35 and 50, but cognitive
functioning outside these limits may occur [4].
Craniospinal and posterior fossa abnormalities have been
commonly reported in association with RTS, including
large foramen magnum, microcranium, spina bifida occulta,
cervical hyperkyphosis, dens hypoplasia, cervical instability
of C1-C2, cervical spondylolisthesis and scoliosis [5].
The association between RTS and Arnold-Chiari
malformation has been described in four patients,
complicated by syrinx in two of them [6-8].
Affected patients are also characterised by short stature
with indirect measures of growth hormone usually found
normal. There are no descriptions of growth hormone
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(GH) deficiency in this syndrome and therefore data on
the need, effectiveness, or safety of growth hormone in
children with this syndrome are not yet available in
literature.
Molecular and genetic basis
The first descriptions of cytogenetic anomaly in RTS were
in 1991 [9-11]. The syndrome is autosomal dominant but
reports of transmission are rare, the overwhelming major-
ity of cases being caused by de novo mutations [12,13].
The known genetic causes are mutations of the genes
CREBBP (OMIM 600140, cAMP-response-element binding
protein-BP), located at chromosome 16p13.3 and EP300
(OMIM 602700, E1A-binding protein), a CREBBP homo-
log, located at chromosome 22q13.2.
CREBBP mutations are found in 50-60% and EP300
mutations in 5% of RTS cases [14,15]. The CREBBP gene
is involved in different signalling pathways and in certain
cellular functions, such as DNA repair, cell growth, dif-
ferentiation, apoptosis and tumor suppression.
The mutational spectrum is represented mainly from
frameshift, nonsense, splice site and missense mutations.
Less frequently large deletions (of one or more exons)
and rarely balanced inversions and translocations have
been found. Mutations may remove 5′ or the 3′ end of
CREBBP and adjacent genomic segments, which causes
the 16p13.3 contiguous gene deletion syndrome [16-18].
The genetic cause of RTS remains unknown in about
40% of the patients.
Case presentation
We report a RTS girl born at gestional age of 38 weeks.
Her birth weight and her length were 2,830 g and 48 cm
respectively. Her newborn features included broad
thumbs and toes, hypoplastic maxilla, malpositioned ears
with dysplastic helices and hypertelorism.
Mutational analysis showed a frameshift mutation
(c.3546insCC) of the CREBBP gene due to the insertion
of two cytosines. This mutation, never described in lit-
erature, leads to a stop codon which probably causes
nonsense mediated decay.
During childhood she showed growth and develop-
ment delay. At the age of 11-year-old, when she came to
our attention after being lost to follow-up, the stature
was −3.5 standard deviation score (sds), the weight was
between 10°-25° percentile, bone age, obtained by X-ray
of non dominant hand and wrist and determined by
TW2 method, was 9 years.
Pubertal Tanner stage was PH1 B1. She had scoliosis,
mental retardation, microcephaly, long eyelashes, high-
arched palate, beaked nose, duplication of terminal phal-
anx (Figure 1) of the thumbs.
Thyroid function was normal, cortisol levels at 8:00 a.m.
and sexual hormones were normal for the age. Because
of low IGF-1 (< 3° percentile), an arginine and then a
clonidine provocative test for GH secretion were
performed. GH peak levels were both < 7 ng/dL showing
a GH deficiency. She started GH therapy at the dosage
of 0.020 mg/kg/day with good improvement of growth
velocity.
When she was 14-year-old, the stature was −2.7 sds and
the weight between 3°-10° percentile. Bone age showed a
delay of 1.5 years. Pubertal Tanner stage was PH2 B2. A
brain magnetic resonance (MRI), performed as soon as the
patient was cooperative enough not to require narcosis and
parents gave their consent, showed pituitary hypoplasia
(Figure 2) and Arnold Chiari malformation type1 (Figure 3).
A medullary MRI scan showed a double syringomyelic
cavity (Figure 4) requiring surgical treatment. Interestingly,
we observed the complete absence of symptoms related to
Arnold Chiari malformation and syrinx.
At 16-year-old, GH dose had been increased to
0.033 mg/Kg/day and the stature of the patient was −2.1
sds (Figure 5), the grade of scoliosis was constant. No
side effects appeared during GH treatment.
Discussion
The distinctive feature of the RTS girl we describe is
the concurrent presence of GH deficiency, pituitary
Figure 1 This hand wrist radiograph was made when she was
14 years old. The arrow shows a duplication of terminal phalanx of
the thumb.
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hypoplasia, Arnold Chiari malformation type 1 and
double syringomyelic cavity. The presence of pituitary
hypoplasia and GH deficiency in RTS patient, has
never been reported so far.
Although frameshift and/or stop codons in CREBBP
gene have been reported in literature, the mutation we
have found is novel [6]. This case adds new clinical
pieces to the syndromic puzzle of this rare syndrome.
Arnold-Chiari malformation
RTS is associated with craniocervical and spinal cord
complications. In literature patients with RTS affected
by os odontoideum, C1-C2 instability, dens hypoplasia,
scoliosis, cervical myelopathy, Chiari malformation,
tethered spinal cord, large foramen magnum, vertebral
fusion, microcranium, craniovertebral junction stenosis
have been described [6,19,20].
The most serious consequences of Arnold Chiari malfor-
mation are attributable to syringomyelia formation with
dysesthesias, paresthesias, anesthesias, incontinence, motor
weakness, headache, abnormal reflexes as presenting signs
[21]. However, our patient did not show any of these
symptoms.
Little literature exists linking RTS to the occurrence
of Chiari malformation. A case report examined a 2-
year-old patient with RTS and a Chiari I malformation
without syrinx who presented with a microdelection of
16p13.3 involving the CREBBP gene and additionally
ADCY9 and SRL genes. The authors of this article
postulated that the Chiari I malformation may be
related to a contiguous gene syndrome associating the
haploinsufficiency of the neighboring genes to the eti-
ology of Chiari malformation [8]. Another case report
involving a 4-year-old Korean-Japanese RTS patient
with a genetically confirmed CREBBP gene mutation
with a C insertion in exon 31 discovered a Chiari I
malformation. No syrinx was described in this patient’s
imaging [7].
Finally, a recent case report described 13-year-old iden-
tical twin girls with RTS, Chiari malformation and exten-
sive multioculated spinal cord syrinxes. The twins were
both confirmed to possess an identical p.Arg2004 gene
Figure 2 The arrow indicates the pituitary gland, which
is hypoplastic.
Figure 3 The arrow shows Arnold Chiari malformation type 1.
Figure 4 In this image, two syringomyelic cavity are evident,
one of these is to cervical level, C5-T2 (thick arrow), and the
other one to dorsal level, T5-T9 (thin arrow).
Marzuillo et al. BMC Medical Genetics 2013, 14:28 Page 3 of 6
http://www.biomedcentral.com/1471-2350/14/28
mutation in the CREBBP gene that is predicted to cause
loss of normal protein function through premature pro-
tein truncation [6].
Since our patient also had a nonsense mutation in
CREBBP leading to a premature stop codon, Chiari mal-
formation and syrinx, this excludes the possibility of a
contiguous gene syndrome (RTS + Chiari malformation +
syrinx) previously postulated and confirms the single gene
effect of CREBBP gene mutation.
Growth hormone deficiency and pituitary hypoplasia
This is the first report of GH deficiency in a RTS patient.
Indirect measures of growth hormone secretion have
usually been reported normal in individuals with RTS in
literature [20] but these patients have never been tested
for growth hormone deficiency by dynamic testing.
Although the association between growth hormone
deficiency and RTS could be coincidental, there are
some possible pathogenic links between GH deficiency
Figure 5 Growth of the patient during the GH therapy.
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and RTS. CREBBP mutations could influence growth
hormone secretion at multiple levels of the hypothalamic-
pituitary-somatomedin axis, including both the hypothal-
amus and pituitary. A study using conditional cAMP
response element binding protein (CREB) mutant mice
showed that selective loss of the CREB transcription
factor in all the brain except pituitary resulted in reduced
postnatal growth consistent with dwarfism caused by
GH deficiency and consequent reduction in IGF-1
mRNA expression in the liver. In addition the authors
demonstrated that mice with CREB mutation exhibited
pituitary hypoplasia. These findings show that CREB is
required for the efficient function and development of
pituitary probably having an effect at hypothalamic
level, as CREB expression in pituitary in this animal
model was normal [22,23]. Since CREBBP is an import-
ant CREB co-activator, the possibility exists that also
CREBBP mutations at hypothalamic level can play a role
in GH deficiency and pituitary hypoplasia. It has been
demonstrated that, at pituitary level, CREBBP interacts
as cofactor with Pit-1. Pit-1 is an important transcription
factor that promotes growth hormone and stimulates
somatic growth [24]. Therefore, an impairment of
CREBBP/Pit-1 interaction could affect pituitary devel-
opment and/or GH secrection.
Conclusions
We propose that, since in this syndrome there is develop-
ment delay with sometimes incapacity to describe
symptoms, MRI imaging screening for Chiari malforma-
tion should be performed in all RTS patients at the first
signs and/or suggestive symptoms (headache, neck pain,
vertigo, sensory changes and ataxia or poor coordination)
or, if asymptomatic, when patients are cooperative enough
not to require narcosis (63% of patients with Chiari
malformation can be asymptomatic) [25]. If patients have
severe mental retardation, to strengthen the indication to
perform an MRI, it could be useful, to use pain scales spe-
cific for children with severe cognitive impairment [26] to
evaluate possible signs of discomfort related to Arnold-
Chiari malformation.
To discriminate if there is a causal link between growth
hormone deficiency and RTS, it could be interesting to
study GH secretion in more patients with RTS to disclose
if GH deficiency could play an causative role in short
stature in RTS patients with CREBBP mutation.
Finally, the possibility exists that CREBBP gene mutation
could be responsible both for GH deficiency and pituitary
hypoplasia in our patient.
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